Edition:
United Kingdom

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

75.64USD
19 Jun 2018
Change (% chg)

$1.28 (+1.72%)
Prev Close
$74.36
Open
$73.80
Day's High
$75.66
Day's Low
$73.80
Volume
278,045
Avg. Vol
333,593
52-wk High
$95.82
52-wk Low
$63.69

Latest Key Developments (Source: Significant Developments)

Perrigo Confirms Patent Challenge For Generic Version Of Sernivo Spray, 0.05%
Thursday, 24 May 2018 

May 24 (Reuters) - Perrigo Company PLC ::PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF SERNIVO SPRAY, 0.05%.PERRIGO COMPANY - PROMIUS PHARMA LLC INITIATED PATENT LITIGATION ON MAY 22, 2018 IN COURT.PERRIGO COMPANY - PATENT LITIGATION REGARDING PERRIGO'S PARAGRAPH IV ABBREVIATED NEW DRUG APPLICATION FOR BETAMETHASONE DIPROPIONATE, 0.05% SPRAY.  Full Article

Perrigo Confirms First To File Patent Challenge For Generic Ultravate Lotion
Monday, 14 May 2018 

May 14 (Reuters) - Perrigo Company PLC ::PERRIGO CONFIRMS FIRST TO FILE PATENT CHALLENGE FOR GENERIC VERSION OF ULTRAVATE LOTION, 0.05%.PERRIGO COMPANY PLC - SUN PHARMACEUTICAL INDUSTRIES & MICAL PHARMACEUTICALS INITIATED PATENT LITIGATIONS ON MAY 9 & 10, 2018.PERRIGO COMPANY PLC - LITIGATIONS REGARDING PARAGRAPH IV ABBREVIATED NDA FOR HALOBETASOL PROPIONATE LOTION, 0.05%.  Full Article

Perrigo Company Reports Q1 Adjusted EPS Of $1.26 Excluding Items
Tuesday, 8 May 2018 

May 8 (Reuters) - Perrigo Company PLC ::REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 GAAP EARNINGS PER SHARE $0.57.Q1 EARNINGS PER SHARE VIEW $1.16 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $5.05 TO $5.45.SEES FY 2018 EARNINGS PER SHARE $2.90 TO $3.30.Q1 ADJUSTED EARNINGS PER SHARE $1.26 EXCLUDING ITEMS.Q1 SALES $1.2 BILLION VERSUS I/B/E/S VIEW $1.21 BILLION.SEES FY 2018 SALES $5.0 BILLION TO $5.1 BILLION.FY2018 EARNINGS PER SHARE VIEW $5.26, REVENUE VIEW $5.06 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Perrigo Company PLC ::SAYS LAUNCH OF STORE BRAND OMEPRAZOLE DELAYED RELEASE ORALLY DISINTEGRATING TABLETS 20MG.  Full Article

Perrigo Says Terminated Existing Credit Agreements
Friday, 9 Mar 2018 

March 9 (Reuters) - Perrigo Company Plc ::PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT.PERRIGO SAYS ‍NEW CREDIT AGREEMENTS PROVIDE FOR $1.0 BILLION SENIOR UNSECURED REVOLVING LINE OF CREDIT, EUR350 MILLION IN SENIOR UNSECURED TERM LOAN FINANCING​.  Full Article

Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo Gel
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Perrigo Company Plc ::PERRIGO ANNOUNCES FINAL FDA APPROVAL AND LAUNCH OF AN AB RATED GENERIC VERSION OF EPIDUO GEL.  Full Article

Perrigo Says In Connection With Uwe Röhrhoff's Appointment As CEO, Co's Unit Perrigo DAC Entered Into Employment Agreement With Him
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY - IN CONNECTION WITH UWE RÖHRHOFF'S APPOINTMENT AS CEO, CO'S UNIT PERRIGO DAC ENTERED INTO AN EMPLOYMENT AGREEMENT WITH HIM.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT HAS AN INITIAL TERM OF THREE YEARS.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT PROVIDES THAT RÖHRHOFF WILL BE ENTITLED TO AN ANNUAL BASE SALARY OF EUR 850,000.PERRIGO COMPANY PLC - RÖHRHOFF WILL ALSO RECEIVE A EUR 850,000 SIGN-ON BONUS, TO BE PAID EUR 425,000 IN CASH AND EUR 425,000 IN RSUS.PERRIGO SAYS RÖHRHOFF TO BE ENTITLED TO TARGET ANNUAL BONUS OPPORTUNITY OF NO LESS THAN 125% OF ANNUAL BASE SALARY- SEC FILING.  Full Article

Perrigo appoints Uwe Röhrhoff as CEO
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO APPOINTS UWE RÖHRHOFF AS PRESIDENT & CHIEF EXECUTIVE OFFICER.PERRIGO COMPANY- ‍ANNOUNCED APPOINTMENT OF UWE RÖHRHOFF AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 15, 2018, FOLLOWING RETIREMENT OF JOHN T. HENDRICKSON​.‍JOHN T. HENDRICKSON TO REMAIN WITH COMPANY UNTIL MARCH 15, 2018 TO ENSURE SUCCESSFUL TRANSITION​.  Full Article

Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07%
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Perrigo Company Plc ::PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF PROLENSA® OPHTHALMIC SOLUTION 0.07%.  Full Article

Perrigo Company ‍Launch AB Rated Generic Version Of Exalgo 32mg
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY PLC - ‍LAUNCH OF AN AB RATED GENERIC VERSION OF EXALGO 32MG EXTENDED RELEASE TABLETS C-II​.  Full Article